Hansa Biopharma AB (publ) (HNSBF) News Today $3.65 0.00 (0.00%) (As of 11/27/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Hansa Biopharma Reports Third Quarter and Interim January - September 2024 Financial ResultsOctober 17, 2024 | prnewswire.comHansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | prnewswire.comHansa Biopharma AB: Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew ShaulisAugust 24, 2024 | finanznachrichten.deHansa Biopharma Announces Departure of Chief Commercial Officer, Matthew ShaulisAugust 23, 2024 | prnewswire.comHansa Medical AB is about to announce its earnings — here's what to expectJuly 19, 2024 | markets.businessinsider.comHansa Biopharma AB: Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business UpdateJuly 19, 2024 | finanznachrichten.deHansa Biopharma Reports Second Quarter 2024 Financial Results and Business UpdateJuly 18, 2024 | prnewswire.comHansa Biopharma to present data at 2024 American Transplant Congress annual meetingMay 21, 2024 | finance.yahoo.comHansa Biopharma: increase in number of shares and votesMay 3, 2024 | prnewswire.comHansa Biopharma interim report January-March 2024April 18, 2024 | prnewswire.comWhat Wall Street expects from Hansa Medical AB's earningsApril 17, 2024 | markets.businessinsider.comXbrane Biopharma AB XBRANEApril 2, 2024 | morningstar.comHansa Biopharma Expects Strong First Quarter 2024 Sales PerformanceApril 2, 2024 | prnewswire.comHansa Biopharma publishes 2023 Annual and Sustainability ReportsMarch 21, 2024 | finance.yahoo.comEvan Ballantyne to join Hansa Biopharma as Chief Financial OfficerFebruary 22, 2024 | prnewswire.comHansa Biopharma AB (publ) 2023 Q4 - Results - Earnings Call PresentationFebruary 6, 2024 | seekingalpha.comHansa Medical AB earnings: here's what to expectFebruary 1, 2024 | markets.businessinsider.comHansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare ConferenceJanuary 6, 2024 | finance.yahoo.comHansa Biopharma AB HNSADecember 16, 2023 | morningstar.comImlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantationDecember 14, 2023 | finance.yahoo.comImlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)December 7, 2023 | finance.yahoo.comUpdate on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patientsOctober 13, 2023 | finance.yahoo.comHansa Biopharma AB: Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patientsOctober 11, 2023 | finanznachrichten.deHansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487October 9, 2023 | finance.yahoo.comDr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa BiopharmaSeptember 1, 2023 | finance.yahoo.comHansa Biopharma half year report 2023July 20, 2023 | finance.yahoo.comFirst patient treated with imlifidase in an investigator-initiated Phase 2 study in ANCA-associated vasculitisJuly 19, 2023 | finance.yahoo.comIdefirix (imlifidase) receives provisional approval in Australia as desensitization treatment in highly sensitized patients prior to kidney transplantationJuly 11, 2023 | finance.yahoo.comHansa Biopharma to host conference call to provide half year results for January-June 2023 and a Business UpdateJuly 6, 2023 | benzinga.comHansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company - no impact on the consolidated financialsJuly 4, 2023 | finance.yahoo.comHansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantationJune 1, 2023 | finance.yahoo.comHansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) diseaseMay 30, 2023 | finance.yahoo.comHansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodiesApril 27, 2023 | finance.yahoo.comHansa Biopharma provides Q1 updateApril 20, 2023 | msn.comHansa Biopharma interim report January-March 2023April 20, 2023 | finance.yahoo.comHansa Biopharma AB (publ) (0RC7.IL)March 30, 2023 | ca.finance.yahoo.comHansa Biopharma announces positive reimbursement decision in Spain for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantationMarch 29, 2023 | finance.yahoo.comMatthew Shaulis appointed Chief Commercial Officer and US President of Hansa BiopharmaMarch 3, 2023 | finance.yahoo.comHansa Biopharma AB (publ) (HNSA.ST)February 10, 2023 | finance.yahoo.comHansa Biopharma Year-end report January-December 2022February 2, 2023 | finance.yahoo.comHansa Biopharma announces positive reimbursement decision for Idefirix® (imlifidase) in the Czech RepublicJanuary 2, 2023 | finance.yahoo.comHansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantationDecember 8, 2022 | finance.yahoo.comHansa Biopharma announces positive topline data from the imlifidase phase 2 study in antibody mediated rejection (AMR) episodes post kidney transplantationNovember 28, 2022 | finance.yahoo.comHansa Biopharma and partner Sarepta Therapeutics plan to initiate a clinical study with imlifidase as a pre-treatment to Sarepta's SRP-9001 gene therapy in DMD in 2023November 3, 2022 | finance.yahoo.comHansa Biopharma Interim report January-September 2022October 20, 2022 | finance.yahoo.comHansa Biopharma: Increase of the number of shares and votesSeptember 30, 2022 | finance.yahoo.comHansa Biopharma to host conference call to provide interim results for January-September 2022 and Business UpdateSeptember 30, 2022 | finance.yahoo.comUBX Unity Biotechnology, Inc.September 20, 2022 | seekingalpha.comThe Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma's Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patientsSeptember 12, 2022 | finance.yahoo.comHansa Biopharma: Issue and repurchase of class C shares for incentive programsSeptember 9, 2022 | finance.yahoo.com Get Hansa Biopharma AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for HNSBF and its competitors with MarketBeat's FREE daily newsletter. Email Address The latest trend in real estate (Ad)These vacation homes are often expensive to maintain and vacant 90% of the year. But thanks to co-ownership, they’re being transformed into fully utilized assets. And there’s one company that’s leading the charge – already welcoming over 1,500 happy homeowners into their co-ownership family, earning $100M in gross profits along the way. Now, for the first time, this innovative company is opening its doors to public investors. Want to learn more about co-ownership and its potential? Check them out – but be aware: their share price is set to change December 5, so you don’t have long to maximize your stake. Don’t miss your chance to maximize your stake in this co-ownership revolution. HNSBF Media Mentions By Week HNSBF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HNSBF News Sentiment▼0.000.77▲Average Medical News Sentiment HNSBF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HNSBF Articles This Week▼00▲HNSBF Articles Average Week Get Hansa Biopharma AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for HNSBF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AGNPF News Today AKBLF News Today DRTSW News Today ARNI News Today ASPHF News Today ASCLF News Today AVCTF News Today AWKNF News Today AXIM News Today BRRGF News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:HNSBF) was last updated on 11/28/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored140% Yields From Stocks Like Tesla? Here's How (Black Friday Special)140% Dividends from stocks like Tesla? Discover How for Just $9! For Black Friday, get the full details of ...Investors Alley | SponsoredThe Biggest Post-Election Market Shift Ever?Our No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | SponsoredThe Trump Surge-SectorsIt's already responsible for the greatest stock market achievements in history. It predicted President Trump's...InvestorPlace | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hansa Biopharma AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Hansa Biopharma AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
